These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 61631)

  • 1. The effect of antithrombin III on the activity of the coagulation factors VII, IX and X.
    Osterud B; Miller-Andersson M; Abildgaard U; Prydz H
    Thromb Haemost; 1976 Apr; 35(2):295-304. PubMed ID: 61631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of pentosan polysulphate (SP54) and heparin. I: Mechanism of action on blood coagulation.
    Fischer AM; Barrowcliffe TW; Thomas DP
    Thromb Haemost; 1982 Apr; 47(2):104-8. PubMed ID: 6179182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of bovine factor IXa and factor Xabeta by antithrombin III.
    Kurachi K; Fujikawa K; Schmer G; Davie EW
    Biochemistry; 1976 Jan; 15(2):373-7. PubMed ID: 1247523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A coagulation pathway on bovine aortic segments leading to generation of Factor Xa and thrombin.
    Stern DM; Nawroth PP; Kisiel W; Handley D; Drillings M; Bartos J
    J Clin Invest; 1984 Dec; 74(6):1910-21. PubMed ID: 6439737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of activated factors II, VII, IX, and X by synthetic organic compounds directed against the active-site seryl residue.
    Van der Woerd-de Lange JA; van Dam-Mieras MC; Hemker HC
    Haemostasis; 1981; 10(6):315-47. PubMed ID: 6976920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated factor IX-antithrombin III complexes in human blood: quantification by an enzyme-linked differential antibody immunoassay and determination of the in vivo half-life.
    Takahashi I; Kato K; Sugiura I; Takamatsu J; Kamiya T; Saito H
    J Lab Clin Med; 1991 Oct; 118(4):317-25. PubMed ID: 1940573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombin III. Theory and clinical applications. H. P. Smith Memorial Lecture.
    Seegers WH
    Am J Clin Pathol; 1978 Apr; 69(4):299-359. PubMed ID: 347919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.
    Lämmle B; Griffin JH
    Clin Haematol; 1985 Jun; 14(2):281-342. PubMed ID: 2994929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of heparin and heparinlike molecules in thrombosis and atherosclerosis.
    Rosenberg RD
    Fed Proc; 1985 Feb; 44(2):404-9. PubMed ID: 3155697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GAGs-potentiated inhibition of thrombin, factor Xa and plasmin in plasma and in a purified system containing antithrombin III - correlation with total charge density.
    Cofrancesco E; Vigo A; Pogliani EM
    Thromb Haemost; 1981 Dec; 46(4):749-51. PubMed ID: 6460339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of activated coagulation factor VII by normal human plasma.
    Dahl PE; Abildgaard U; Larsen ML; Tjensvoll L
    Thromb Haemost; 1982 Dec; 48(3):253-6. PubMed ID: 7164015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of human factor VII by activated factors IX and X.
    Masys DR; Bajaj SP; Rapaport SI
    Blood; 1982 Nov; 60(5):1143-50. PubMed ID: 7126868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proceedings: The relationship between antithrombin III, progressive antithrombin activity and anti Xa activity in plasma.
    Whigham K; Howie PW; Forbes CD; Prentice CR
    Thromb Diath Haemorrh; 1975 Sep; 34(1):365. PubMed ID: 52904
    [No Abstract]   [Full Text] [Related]  

  • 14. The activation of human factor IX.
    Osterud B; Laake K; Prydz H
    Thromb Diath Haemorrh; 1975 Jun; 33(3):553-63. PubMed ID: 239460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effect of heparin in thrombin-antithrombin III interaction.
    Marciniak E
    Thromb Diath Haemorrh; 1975 Dec; 34(3):748-62. PubMed ID: 1209544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors.
    Fuchs HE; Trapp HG; Griffith MJ; Roberts HR; Pizzo SV
    J Clin Invest; 1984 Jun; 73(6):1696-703. PubMed ID: 6202716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered recombinant factor VII Q217 variants with altered inhibitor specificities.
    Chang YJ; Hamaguchi N; Chang SC; Ruf W; Shen MC; Lin SW
    Biochemistry; 1999 Aug; 38(34):10940-8. PubMed ID: 10460149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enhanced activity of diminished blood clotting factors in inborn blood coagulation defects].
    Mingers AM; Mietens C; Ströder J
    Thromb Diath Haemorrh; 1971 Jun; 25(2):316-31. PubMed ID: 5568051
    [No Abstract]   [Full Text] [Related]  

  • 19. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients.
    Xi M; Béguin S; Hemker HC
    Thromb Haemost; 1989 Sep; 62(2):788-91. PubMed ID: 2814925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibition of activated bovine coagulation factors X and VII by antithrombin III.
    Jesty J
    Arch Biochem Biophys; 1978 Jan; 185(1):165-73. PubMed ID: 564164
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.